Non Small Cell Lung Cancer Metastatic, Platinum Resistant Ovarian Cancer
Conditions
Brief summary
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) were enrolled in the expansion segment of this study. Patients with platinum-resistant, high-grade serous ovarian cancer were enrolled in the UPLIFT segment of this study. In addition to safety assessments, the pharmacokinetics of the drug were assessed along with ADC activity. A QTc sub-study was added for the UPLIFT cohort for a sub-set of sites.
Detailed description
This is a multi-center study of XMT-1536 (upifitamab rilsodotin) in patients with tumors likely to express NaPi2b, focusing on patients with platinum-resistant ovarian cancer and non-small cell lung cancer, adenocarcinoma subtype. XMT-1536 (upifitamab rilsodotin) was administered as an intravenous infusion once every four weeks. The study consisted of three segments: dose escalation (DES), dose expansion (EXP), and the pivotal cohort (UPLIFT). The DES segment studied small groups of patients who received increased doses. A Safety Review Committee was established to review the data from each dose level before moving to the next higher dose. The dose escalation cohort has ended and is no longer enrolling patients. Enrollment into the EXP segment consisted of 2 parallel cohorts of patients to confirm the dose that has been identified in DES and estimate the objective response rate in each patient population. The EXP and UPLIFT cohorts are no longer enrolling patients. All adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria version (CTCAE v5.0). Throughout the study, pharmacokinetics were measured using proprietary assays developed by Mersana. Anti-cancer activity were measured via RECIST.
Interventions
XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study. For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536
Sponsors
Mersana Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Open-label, dose escalation to reach MTD. The MTD will be confirmed in parallel cohorts: patients with platinum-resistant ovarian cancer; patients with non-squamous NSCLC, adenocarcinoma subtype
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
General Inclusion Criteria (for Dose Escalation, Expansion, and UPLIFT): * ECOG performance status 0 or 1 * Measurable disease as per RECIST, version 1.1 * Resolution of all acute toxic effects of prior therapy or surgical procedures to ≤Grade 1 (except alopecia, stable immune-related toxicity such as hypothyroidism on hormone replacement, adrenal insufficiency on ≤10 mg daily prednisone \[or equivalent\], chronic Grade 2 peripheral sensory neuropathy after prior taxane therapy). * Cardiac left ventricular ejection fraction (LVEF) ≥50% or ≥ the institution's lower limit of normal by either Echo or MUGA scan * Adequate organ function as defined by the following criteria: 1. Absolute neutrophil count (ANC) ≥1500 cells/mm3 2. Platelet count ≥100,000/mm3 3. Hemoglobin ≥9 g/dL 4. In patients not on anticoagulation therapy: INR, activated partial thromboplastin time (aPTT), and prothrombin time (PT) all within 1.2 times the institution's upper limit of normal (ULN). Patients on anticoagulation therapy are allowed if their relevant laboratory values are within the therapeutic window. 5. Estimated glomerular filtration rate (GFR) ≥45 mL/min 6. Total bilirubin ≤ULN 7. g. Patients with asymptomatic elevations in unconjugated bilirubin due to Gilbert syndrome or stable chronic hemolytic anemia (e.g., hereditary spherocytosis, sickle cell disease, thalassemia intermedia) may be eligible after discussion with the Sponsor Medical Monitor. * Aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) ≤1.5 times the institutional ULN. * Albumin ≥3.0 g/dL * Able to provide informed consent. General
Exclusion criteria
(for Dose Escalation, Expansion, and UPLIFT) : * Major surgery within 28 days of starting study treatment, systemic anti-cancer therapy within the lesser of 28 days or 5 half-lives of the prior therapy before starting study treatment, or recent radiation therapy with unresolved toxicity or within a time window of potential toxicity. * Patients with untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis or carcinomatous meningitis. * Current known active infection with HIV, hepatitis B virus, or hepatitis C virus. * Prior history of liver disease such as liver cirrhosis, hepatic fibrosis * Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease) or intercurrent illness that could interfere with per-protocol evaluations. * Current use of either constant or intermittent supplementary oxygen therapy. * History of suspected pneumonitis or interstitial lung disease. * Pregnant or nursing women. * History of other malignancy within the last 2 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome. * Active corneal disease, or history of corneal disease within 12 months prior to enrollment * Use of strong CYP450 3A inhibitors or inducers that cannot be discontinued while receiving study treatment * Oxygen saturation on room air \<93% Ovarian Cancer Inclusion Criteria for UPLIFT: * Histological diagnosis of high grade serous ovarian cancer, which includes fallopian tube, or primary peritoneal cancer, that is metastatic or recurrent. * Platinum-resistant disease 1. Patients who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response \[complete response/remission (CR) or partial response/remission (PR)\], and then progressed between 3 months and ≤ 6 months after the date of the last dose of platinum 2. Patients who have received 2 to 4 lines of prior therapy must have received at least 4 cycles of platinum and then progressed within 6 months after the date of the last dose of platinum * One to 4 prior lines of systemic therapy for ovarian cancer a. Prior treatment with bevacizumab is required for patients with 1 to 2 prior lines of therapy * Patients must be willing to provide an archival tumor tissue block or slides or if not available, undergo procedure to obtain a new tumor biopsy using a low-risk, medically routine procedure Ovarian Cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DES: Maximum tolerated dose or recommended Phase 2 dose | Up to 36 weeks, from the date of first dose until unacceptable side effects or a dose-limiting toxicity is met | Evaluate adverse events and concomitant medication use after XMT-1536 (upifitamab rilsodotin) doses |
| DES and EXP: Safety and Tolerability | First dose up until 30 days after study termination | Evaluate incidence and severity of adverse events |
| EXP: Anti-neoplastic effects of XMT-1536 (upifitamab rilsodotin) | Every 6 weeks for up to 36 weeks | Monitor tumor size |
| UPLIFT: Investigator-assessed objective response rate (ORR) of XMT-1536 (upifitamab rilsodotin) in the ITT-Higher NaPi2b population | Every 8 weeks until disease progression or up to 24 months | Confirmed ORR is defined as the proportion of patients who have achieved a confirmed complete response (CR) or partial response (PR) per RECIST v1.1 after the initiation of study treatment. |
| QTc Sub-study: Evaluation of the concentration response analysis of XMT-1536 versus the change in QTcF values | 60 minutes prior to first dose, up to 26 hours after Cycle 3 dose | The concentration-QTcf change from baseline deltaQTcF analysis and analysis of central tendency for deltaQTcF |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| UPLIFT: Confirmed Investigator-assessed objective response rate of XMT-1536 (upifitamab rilsodotin) regardless of NaPi2b expression | Every 8 weeks until disease progression or up to 24 months | Assess the confirmed investigator-assessed objective response rate of XMT-1536 (upifitamab rilsodotin) regardless of NaPi2b expression |
| UPLIFT: Confirmed objective response rate by independent radiology review (IRR) for patients with high NaPi2b and overall | Every 8 weeks until disease progression or up to 24 months | Assess the confirmed objective response rate by IRR for patients with high NaPi2b (TPS \>/=75) and overall |
| UPLIFT: Duration of objective response (DOR) | 4 weeks after first response and every 8 weeks until disease progression or up to 24 months | Assess the duration of objective response (DOR) in patients who achieve a response |
| DES and EXP: Time of maximum observed concentration of XMT-1536 (upifitamab rilsodotin) | Daily for one week after first dose; weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses | Determine the pharmacokinetics of XMT-1536 (upifitamab rilsodotin) |
| QTc Sub-Study: Evaluation of the effect of XMT-1536 on QTcF in patients with platinum-resistant HGSOC by timepoint analysis | 60 minutes prior to first dose, up to 26 hours after Cycle 3 dose | Con.-QTc evaluation |
| QTc Sub-Study: Evaluation of the effect of XMT-1536 on the PR-interval (PR), QRS duration (QRS), Heart Rate (HR), and ECG morphology | 60 minutes prior to first dose, up to 26 hours after Cycle 3 dose | Con.-QTc evaluation |
| UPLIFT: Incidence and severity of adverse events | First dose up until 60 days after study termination | Evaluate incidence and severity of adverse events |
| DES and EXP: Maximum concentration of XMT-1536 (upifitamab rilsodotin) | Daily for one week after first dose; weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses | Determine the pharmacokinetics of XMT-1536 (upifitamab rilsodotin) |
| DES and EXP: Area under the concentration curve of the last measurable concentration of XMT-1536 (upifitamab rilsodotin) | Daily for one week after first dose; weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses | Determine the pharmacokinetics of XMT-1536 (upifitamab rilsodotin) |
| DES: Anti-neoplastic effects of XMT-1536 (upifitamab rilsodotin) | Every 6 weeks for up to 36 weeks | Monitor tumor size |
| DES and EXP: Anti-drug antibody and neutralizing antibody | Every 6 weeks for up to 36 weeks | Analyze blood for antibodies to XMT-1536 (upifitamab rilsodotin) and neutralizing antibodies |
Countries
United States
Outcome results
None listed